- PROFESSOR Medicine, Cardiology
MBBS, Kasturba Medical College
Internship, Internal Medicine
Kasturba Medical College
University of Wales College of Med
Residency, Internal Medicine
Our Lady of Mercy Med. Center/ Montefiore North
Mount Sinai Hospital
Fellowship, Cardiovascular Dis.
Mount Sinai Hospital
Fellowship, Interventional Radiology
Mount Sinai Hospital
Dr. Annapoorna Kini performs over 1,000 minimally invasive coronary interventions annually (the highest number by a female interventionalist in the United States) with extremely low complication rate, less than 0.5 percent. She is well known for performing the complex coronary interventions in advanced heart disease patients with utmost safety and excellent long-term results. Many of these high-risk patients require the support of heart assist (Tandem Heart) device and she has become the national expert for the use of this lifesaving technology. Dr. Kini also specializes in the non-coronary interventions of mitral and aortic balloon valvuloplasty, and alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
As Director of the The Cardiac Catheterization Lab at The Mount Sinai Hospital she is responsible for day-to-day smooth functioning of very high volume Cardiac Cath Lab which performs more than 15,000 total procedures including 5,200 interventions. Dr. Kini also serves as the Director of Interventional Cardiology Fellowship Program involving six-to-seven fellows from the United States and overseas. Mount Sinai fellowship is one of the largest and Dr. Kini is responsible for selection and training of these fellows.
Along with Dr. Sharma, Dr. Kini played a key role in starting the Live Symposium of Complex Coronary Cases in 1998, which has had overwhelming success every year by performing live complex coronary cases. She is the co-director of the Live Symposium since it's inception and has served as the organizer, planner, and performer of the live cases.
Dr. Kini is widely published on various topics of Interventional Cardiology, including peri-procedural enzyme elevations, rotational atheretomy, Tandem heart and other newer devices, contrast nephropathy, valvuloplasties. She has authored numerous book chapters in the field of acute coronary syndrome and coronary interventions. She serves as the site Principal Investigator for numerous multicenter trials including NIH sponsored COPES trial. She maintains a large interventional database more than 10,000 PCI patients, which helps in analysis and publications of short and long term outcomes after all kinds of coronary interventions.
Dr. Kini is recipient of the Young Investigator Award of American Association of Cardiology of Indian Origin (AAICO) in 1999.
Dr. Kini received her medical degree from Kasurba Medical College, Mangalore, India. She was the best outgoing student having received three honors and gold medals. She then strengthened her clinical Cardiology in England and become the member of Royal College of Physicians of London. She came to Mount Sinai, New York in 1996 and underwent further training in Cardiology under Dr. Valentin Fuster and Interventional Cardiology under Dr. Samin Sharma.
Kini A, Kim M, Sharma S, Krishnan P, Ivan O, Moreno P. Comparison of Coronary Flow Reserve and Fractional Flow Reserve in Patients With Versus Without Diabetes Mellitus and Having Elective Percutaneous Coronary Intervention and Abciximab Therapy (From the PREDICT Trial). Am J Cardiol 2008;.
Kini A, Moreno P, Steinheimer A, Sharma S, Suleman J, Kim M, Prattipati M. Effectiveness of the Stent Pull-Back Technique for Non-Aorto Ostial Coronary Narrowings. Am J Cardiol 2005; 96: 1123-1128.
Lee P, Kini A, Sharma S, Fisher E, Ahsan C. Anemia is an independent predictor of mortality after percutaneous coronary intervention. J Am Col Cardiol 2004; 44: 541.
Kini A, Lee P, Marmur J, Sharma S, Duffy M, Kim M, Agarwal A. Correlation of postpercutaneous coronary intervention creatine Kinase-MB and Troponin I elevation in predicting mid-term mortality. Am J Cardiol 2004; 93: 18.
Kini A, Lee P, Sharma S, Duffy M, Mitre C. Post-procedure chest pain following coronary stenting: Implications on clinical restenosis. J Am Coll Cardiol 2003; 41: 33.
Kini A, Richard M, Suleman J, Sharma SK, Lee P, Kamran M, Marmur JD, Perez N. Effectiveness of tirofiban, eptifibatide, abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). Am J Cardiol 2003; 41: 33.
Kini A, Sharma S, Mitre C, Reich D. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria. Am J Cardiol 2001; 88: 1287.
Kini A, Sharma S, Marmur J, Reich D. Does abciximab limit the CK-MB elevation after rotational atherectomy of type B2 lesions? Results of the Rota ReoPro randomized trial. Am Heart J 2001; 142: 965.
Kini A, Marmur J, Kini S, Dangas G, Sharma S, Cocke T, Brown E, Ambrose J, Wallenstein S. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis and low-to-medium level elevation has a benign clinical course: Implication for early discharge after coronary intervention. J Am Coll Cardiol 1999; 34: 663.
- Coronary Assessment by Near infrared of Atherosclerotic Rupture-prone Yellow [CANARY Trial]
- A non-randomized, single-blinded, open-label, investigator-initiated, pre-marketing, single-center, crossed-over Phase III clinical trial of the 12-Lead ECG Glove (12-LEG) for the assessment of cardiac electrical function. (EKG Glove Study)
- A Prospective Randomized Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS element) for the Treatment of up to Two De Novo Coronary Artery Lesions - PLATINUM Trial
- Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy (YELLOW Trial)
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Kini did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Klingenstein Clinical Center Floor 6th Room 6-63
1450 Madison Avenue
New York, NY 10029
1190 Fifth Avenue - 1 South
New York, NY 10029
- Wednesday 12:00pm - 2:00pm
- Indian (Hindi)
- Aetna U.S. Healthcare
- Beech Street
- Best Doctor
- CarePlus, LLC
- CenterCare, Inc.
- Devon Health Services
- Empire Blue Cross/Blue Shield
- Fidelis Care NY
- First Health
- Group Health Insurance, Inc.
- Health Insurance Plan (HIP)
- HealthPlus, Inc.
- Island Group
- Local 1199
- Medicaid New Jersey
- MetroPlus Health Plan
- MultiPlan, Inc.
- Neighborhood Health Providers, LLC
- Oxford Health Plans
- Private Healthcare Systems (PHCS)
- Travel Care Services
- United Health Care Empire Plan
- United Healthcare
- WellCare of New York, Inc.
- Master Card
- Personal Check